Setmelanotide
Setmelanotide is a licensed medicine for rare genetic obesity syndromes, with pooled trial evidence and guideline coverage in Bardet-Biedl...
About:
An MC4 receptor agonist approved for rare genetic obesity syndromes.
What does this peptide do?
Supported by randomised human trials. Research focuses on rare genetic obesity.
Rare genetic obesity
An MC4 receptor agonist approved for rare genetic obesity syndromes.
Evidence grade
AHighest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.
What are the benefits and side effects of this peptide
What research says it may help with
- Setmelanotide is a licensed medicine for rare genetic obesity syndromes, with pooled trial evidence and guideline coverage in Bardet-Biedl syndrome.
Who should avoid it
- People who are pregnant or breastfeeding
- Children and adolescents
- People without a confirmed genetic diagnosis, for whom the trial evidence does not apply
- Known hypersensitivity to peptide preparations
See the safety section. Absence of a flag is not evidence of safety.
A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.
How to store this peptide
Supplied as a prefilled syringe in licensed use. Store refrigerated and follow the product leaflet.
Lyophilized storage
Refrigerate at 2–8 °C in the original carton. Do not freeze.
Reconstituted storage
Once in use, may be kept below 30 °C for the period stated on the product label.
Storage Handling
Protect from light. Do not use if it has been frozen.
Related research
Related research is coming soon for this peptide.
Related peptides
MetabolicTirzepatide
Dual GIP/GLP-1 receptor agonist studied for weight management and glucose control.
MetabolicSemaglutide
GLP-1 receptor agonist researched for appetite regulation and metabolic health.
MetabolicRetatrutide
Triple-receptor agonist explored for next-generation weight management research.